HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation

This study is testing a combination of a targeted drug (HRS-4642) aimed at a specific mutation called KRAS G12D — a common mutation in pancreatic cancer — together with an anti-cancer antibody (nimotuzumab) and chemotherapy, as a treatment before surgery for patients with borderline resectable (on the edge of being operable) pancreatic cancer. **You may be eligible if...** - You are 18 to 75 years old with pancreatic cancer confirmed by biopsy - Your cancer is borderline resectable (it might be operable with some shrinkage) - Your tumor has tested positive for the KRAS G12D mutation - You have not received any prior systemic cancer treatment - You are in good physical condition (ECOG score 0 or 1) with adequate organ function **You may NOT be eligible if...** - Your cancer has spread to distant organs (metastatic) - Your cancer does not have a KRAS G12D mutation - You have already received chemotherapy or other systemic treatment - Your organ function does not meet study requirements Talk to your doctor to see if this trial is right for you.